A New Strategy for Cardiac Protection

Overview

Journal Elife

Specialty Biology

Date 2023 Nov 2

PMID 37917118

Authors

Esmaa Bouhamida

Hina W Chaudhry

Affiliations

Soon will be listed here.

Abstract

It may be possible to treat cardiac hypertrophy and injury by using drugs that inhibit a protein called SIRT2.

References

Mohamed T, Ang Y, Radzinsky E, Zhou P, Huang Y, Elfenbein A . Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration. Cell. 2018; 173(1):104-116.e12. PMC: 5973786. DOI: 10.1016/j.cell.2018.02.014. View

Tang X, Chen X, Wang N, Wang X, Liang S, Zheng W . SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy. Circulation. 2017; 136(21):2051-2067. PMC: 5698109. DOI: 10.1161/CIRCULATIONAHA.117.028728. View

Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M . Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science. 2007; 315(5812):659-63. DOI: 10.1126/science.1135380. View

Yang X, Chang H, Tatekoshi Y, Mahmoodzadeh A, Balibegloo M, Najafi Z . SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury. Elife. 2023; 12. PMC: 10558204. DOI: 10.7554/eLife.85571. View

Sarikhani M, Maity S, Mishra S, Jain A, Tamta A, Ravi V . SIRT2 deacetylase represses NFAT transcription factor to maintain cardiac homeostasis. J Biol Chem. 2018; 293(14):5281-5294. PMC: 5892579. DOI: 10.1074/jbc.RA117.000915. View

Chaudhry H, Dashoush N, Tang H, Zhang L, Wang X, Wu E . Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium. J Biol Chem. 2004; 279(34):35858-66. DOI: 10.1074/jbc.M404975200. View

Cheng R, Asai T, Tang H, Dashoush N, Kara R, Costa K . Cyclin A2 induces cardiac regeneration after myocardial infarction and prevents heart failure. Circ Res. 2007; 100(12):1741-8. DOI: 10.1161/CIRCRESAHA.107.153544. View

Baur J, Ungvari Z, Minor R, Le Couteur D, de Cabo R . Are sirtuins viable targets for improving healthspan and lifespan?. Nat Rev Drug Discov. 2012; 11(6):443-61. PMC: 4684642. DOI: 10.1038/nrd3738. View

Morciano G, Vitto V, Bouhamida E, Giorgi C, Pinton P . Mitochondrial Bioenergetics and Dynamism in the Failing Heart. Life (Basel). 2021; 11(5). PMC: 8151847. DOI: 10.3390/life11050436. View

10.

Preyat N, Leo O . Sirtuin deacylases: a molecular link between metabolism and immunity. J Leukoc Biol. 2013; 93(5):669-80. DOI: 10.1189/jlb.1112557. View

11.

Bouhamida E, Morciano G, Pedriali G, Ramaccini D, Tremoli E, Giorgi C . The Complex Relationship between Hypoxia Signaling, Mitochondrial Dysfunction and Inflammation in Calcific Aortic Valve Disease: Insights from the Molecular Mechanisms to Therapeutic Approaches. Int J Mol Sci. 2023; 24(13). PMC: 10342149. DOI: 10.3390/ijms241311105. View

12.

Frey N, Katus H, Olson E, Hill J . Hypertrophy of the heart: a new therapeutic target?. Circulation. 2004; 109(13):1580-9. DOI: 10.1161/01.CIR.0000120390.68287.BB. View